AI-Generated Summary

The UK government is considering raising the NHS's drug value threshold by 25%, a move that could increase payments to pharmaceutical companies by billions. This initiative aims to protect Britain's life sciences sector from a potential industry exodus, especially in response to threatened US tariffs by Donald Trump, who has criticized the UK's low medicine prices. The proposed policy faces internal opposition from NHS and Treasury officials due to budget concerns.

In a nutshell

This policy shift highlights the complex interplay between national healthcare budget constraints, international trade pressures, and the strategic imperative to foster domestic pharmaceutical innovation and investment. The potential changes demonstrate a governmental willingness to adjust market access conditions to retain industry competitiveness.

Source: LBC